Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO
A Rich Heyman-backed startup focusing on NASH treatments, as well as other liver, GI and metabolic diseases, is set to start trading Wednesday and join the already-loaded class of 2020 biotech IPOs.
Metacrine has raised $85 million for its public offering after priced shares at $13 apiece, the midpoint of its expected range. Selling 6.5 million shares, Metacrine makes good for a market value of roughly $364 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.